ImmunoGen Undervalued In AbbVie Deal, Shareholder Claims
A shareholder alleges that ImmunoGen Inc. directors and advisers significantly undervalued the company while preparing to sell to AbbVie Inc., including by failing to consider the $1.6 billion in projected revenue...To view the full article, register now.
Already a subscriber? Click here to view full article